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Abstract
During the last decade, there is an increasing usage of quantitative methods in Radiology in an effort to reduce the
diagnostic variability associated with a subjective manner of radiological interpretation. Combined approaches
where visual assessment made by the radiologist is augmented by quantitative imaging biomarkers are gaining
attention. Advances in machine learning resulted in the rise of radiomics that is a new methodology referring to
the extraction of quantitative information from medical images. Radiomics are based on the development of
computational models, referred to as “Radiomic Signatures”, trying to address either unmet clinical needs, mostly in
the field of oncologic imaging, or to compare radiomics performance with that of radiologists. However, to explore
this new technology, initial publications did not consider best practices in the field of machine learning resulting in
publications with questionable clinical value. In this paper, our effort was concentrated on how to avoid
methodological mistakes and consider critical issues in the workflow of the development of clinically meaningful
radiomic signatures.
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Background
In the past decades, medical imaging has proven to be a
useful clinical tool for the detection, staging, and treat-
ment response assessment of cancer. Consequently, con-
ventional imaging is often viewed as “old” technology, a
misperception that unfortunately, has perhaps limited
the harnessing of the full potential of medical images
and their applicability for precision medicine. It is well
known that tumors exhibit substantial phenotypic differ-
ences between and within patients that can be identified
by imaging [1, 2]. A significant advantage of medical im-
aging is its ability to noninvasively visualize a cancer’s
appearance, such as macroscopic tumoral heterogeneity
at baseline and follow-up, for both the primary tumor
and metastatic disease.
In clinical practice, tumors are also often profiled by
invasive biopsy and molecular assays; however, their
spatial and temporal pathologic heterogeneity limits the
ability of invasive biopsies to capture their biological di-
versity or disease evolution [3]. Furthermore, repeated
invasive tumor sampling is burdensome to patients, ex-
pensive and limited by the practical number of tissue
sampling that can be undertaken to monitor disease pro-
gression or treatment response. By contrast, the non-
invasive imaging phenotype potentially contains a wealth
of information that can inform on the expression of the
genotype, the tumor microenvironment and the suscep-
tibility of the cancer to treatments [4, 5].
Radiologists are generating their diagnoses by visually
appraising the images, drawing on past experience and
applying judgment. They perceive and recognize imaging
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patterns and infer a diagnosis consistent with the ob-
served patterns [6]. Not surprisingly, there is a degree of
subjectivity and variability in image interpretation. In an
effort to reduce this variability, alternative approaches
such as quantitative imaging have been proposed,
wherein principle, it is possible to interrogate the images
beyond what the naked eye can see and record measure-
ments that are more objective. However, one of the most
crucial obstacles for quantitative imaging at the moment
is the fact that current scanners are designed to produce
pretty pictures rather than as measurement devices, and
there is limited ability to standardize the way of acquir-
ing imaging data [7].
Tissue biopsy remains the primary source of informa-
tion when it comes to tumor classification and staging.
It is well known that biopsy is prone to sampling errors.
Therefore, it may not be the best way to study tumor
biology, given the fact that cancers are typically hetero-
geneous. On the other hand, imaging provides an oppor-
tunity to extract meaningful information of tumor
characteristics in a non-invasive way. However, most de-
rived images lack microscopic resolution, there is ioniz-
ing radiation exposure for some of the modalities,
radiological assessment can be subjective, extracting
quantitative parameters is time consuming and the
results of these can vary significantly according to the
imaging protocol with low reproducibility.
Hence, there is a clear need to improve the reproduci-
bility and diagnostic accuracy of quantitative imaging
features, and these have been the main driving forces for
the development of radiomics, where we aim to associate
quantitative voxel-wise imaging features with clinical
outcomes and/or disease classification. Machine learning
methods are increasingly applied to build, train, and val-
idate models that can aid in the prediction of disease
and treatment outcomes, as well as patient stratification,
which is at the heart of precision medicine [8]. In the
current review, we present an overview of the consider-
ations and best practice for the development of radiomic
signatures that can bring clinical value to the oncologic
patient.
Pipeline for the development of a Radiomic
signature
A Radiomics investigational pipeline comprises several
phases including i) defining the clinical question and tar-
geting the appropriate patient cohort, ii) identifying the
relevant imaging modalities for radiomics analysis, iii)
optimizing and standardizing the acquisition protocols,
iv) applying pre-processing prior to image analysis, v)
Fig. 1 A multidisciplinary radiomics workflow. Initially a group of clinicians should define the clinical problem that the proposed model should
deal with and make decisions on what kind of imaging modalities should be recruited. Imaging scientists needs to make sure that acquisition
protocols are optimally designed producing high quality images, as well as for the pre-processing of the images. Then depending on the size of
the available imaging studies we need to decide which pipeline to use. In case of big data (in the order of thousands) a deep radiomics
approach can be suggested avoiding tedious and time-consuming processes like tumor segmentation by multiple radiologists. In addition, deep
convolutional neural networks have been proven more efficient to model complex problems compared with traditional machine learning
algorithms, as long as data availability requirement is satisfied. Finally, the data sets are allocated for training, validation and testing purposes
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performing lesion segmentation on the images, vi)
extracting handcrafted or deep imaging features, vii) re-
ducing the dimensionality of the generated data by fea-
ture selection methods, and finally viii) training and
validating the radiomics model (Fig. 1).
Defining the clinical question and targeting the patient
cohort
All radiomics projects should be informed by an appro-
priate clinical question that is underpinned by a scien-
tific hypothesis. The clinical question should seek to
address a current unmet need in cancer management,
where the successful generation of a radiomics signature
could result in better patient stratification, treatment se-
lection and/or defining disease outcomes.
Although sample size matters, data quality is of equal
importance, as well as data diversity. It is surprisingly
difficult even today, where imaging data appears to be
widely available, to be able to collect and curate, high
quality, comprehensive imaging data. The minimum
number of patients that need to be recruited to develop
a radiomics signature is strongly dependent on the com-
plexity of the problem we are trying to address [9]. For
example, disease detection challenges where there is suf-
ficient image contrast resolution to discriminate normal
from abnormal tissue are considered far more straight-
forward and therefore needing fewer patients compared
with more complex problems such as predicting patient
treatment response or disease-free survival.
From a purely statistical viewpoint, for a binary classi-
fication problem, 10 to 15 patients are required for each
feature that is participating within the radiomic signa-
ture [10]. In other words, a 5-feature signature requires
between 50 and 75 patients for model training purposes.
Ideally, 25–40% of the training sample should be the size
of an external validation patient group for testing the
model to estimate its real diagnostic performance.
Radiomics studies have been published with as few as
20–30 patients, making the results of such models highly
questionable due to the risks of model overfitting and
the high instability of such models.
Another important consideration of any radiomics
project is the identification of the patient cohort that is
representative of the target patient population in terms
of disease prevalence or incidence. Clearly, for diseases
with low prevalence or incidence, this approach may not
be pragmatic as very large study populations may be
needed to develop a radiomics signature as useful classi-
fication tool or for predicting disease outcomes. In such
instances, a-priori knowledge of the class sizes of the dif-
ferent disease sub-types that will be categorized by the
radiomics analysis will help to determine whether the in-
vestigation will be useful at the outset. If not, it will be
necessary to enrich the datasets with sufficient cases of
each of disease sub-type for meaningful analysis. On a
practical level, many centers may be limited by the num-
ber of cases that are available for any radiomics analysis
and it is important to appraise the validity of using these
constrained datasets at the outset to avoid wasting time
performing the full analysis without the likelihood of any
meaningful conclusions.
Nonetheless, some degree of heterogeneity when
selecting the study population is inevitable to meet the
high demands of radiomics with regards to the optimal
number of patients that should be included. However,
there is a delicate balance between the latter and the risk
of inefficient learning of the models due to increased
data variability.
Identifying the relevant imaging modalities for radiomics
analysis
A significant issue in quantitative imaging studies is the
high variability of the acquisition protocols and the lack
of standardization [11, 12]. The fundamental design of
imaging modalities by the vendors is based on the as-
sumption that a human will interpret images through
visual perception, which undoubtedly leads to problems
not permitting imaging modalities to act as quantitative
devices that produce standardized quantitative results.
The contributing reasons for the latter is the fact that
measured parameters on images vary depending on the
vendor platform, the type of hardware and software
available on the scanner, the radiographer conducting
the examination, as well as the radiologist performing
the imaging analysis. Hence, comparing results across
institutions can be challenging. Furthermore, there are
now hybrid imaging systems that can produce a wealth
of different imaging contrasts, so careful selection of the
type of images that should be exploited is important for
meaningful results. For example, it is well acknowledged
that CT data is less variable compared with MRI data;
and for this reason, CT images are most widely used for
radiomics analysis.
Optimising and standardising the acquisition protocols
It is important to develop and follow standardized acquisi-
tion protocols that can ensure accurate, repeatable and re-
producible results. The level of standardization is not
possible to be estimated a priori; therefore, a trial and
error approach should be utilized to define such require-
ments. It is almost impossible to know apriori for each
specific problem what is the level of image acquisition
standardization needed. It is advised to generally start
using a more liberal approach accepting a certain amount
of heterogeneity, and only if we can’t identify useful fea-
tures or otherwise called “signal” in our models we intro-
duce certain restrictions in the form of standardized
protocols (vendor, sequence parameter, MRI field
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strength, and others). One way to look at historical
changes related to the image acquisition protocols, com-
petency of scanners that in principle is improving due to
upgrades and updates is the so-called temporal validation
[13]. According to the latter the model training is based
on rather heterogeneous cohort of patients obtained
through the years but testing of the model is done exclu-
sively with recently acquired exams. In this way the model
becomes robust to changes related to the past by “seeing”
diverse examples, although the disadvantage of such an
approach is the higher number of patients needed. In case
of multi-centric studies or in the event of multi-vendor
single center studies there are two strategies. Either train
with data from one site (or vendor) and test with data
from the other sites (or vendors) or use mixed data to do
both training and validation. Again, which of the two
strategies is more effective needs to be proved by trying
both and deciding on the basis of the highest performance
and generalizability [14, 15].
Applying pre-processing prior to image analysis
Preprocessing, including improvement of data quality by
removing noise and artifacts, can improve the perform-
ance of the final models since the “garbage in – garbage
out” concept applies in Radiomics [16]. Different kinds
of filtering methods can be recruited to remove image
noise but these needs to be used carefully since there is
a risk of losing “signal”. Motion correction methods can
cope with 4D data like in CT of the lung [17], diffusion-
weighted imaging or dynamic contrast-enhanced MRI to
remove patient motion from several image acquisitions.
Filtering and motion correction techniques should be
used only as a last resort, and effort should be under-
taken in the image acquisition phase to eliminate the
need of such invasive and in principle destructive
methods. MRI images are known to suffer from spatial
signal heterogeneities that cannot be addressed to bio-
logical tissue properties, rather than to technical factors
like the patient body habitus, the geometric characteris-
tics of external surface coils, the rf pulse profile imper-
fections and so on. Therefore, it is highly recommended
that bias field correction algorithms [18] should be ap-
plied to remove such spatial signal heterogeneity (Fig. 2).
Signal normalization is necessary to bring signal inten-
sities to a common scale, without distorting differences
in the ranges of values. Especially in the setting of het-
erogeneous data coming from different vendors or dif-
ferent acquisition protocols normalization is critical for
the training process. It improves the numerical stability
of the model and often reduces training time and in-
creases model performance [19].
Performing lesion segmentation on the images
After successful image acquisition and preprocessing, the
next phase in the radiomics pipeline is to perform lesion
segmentation in one or all slices containing the target le-
sion. The basic approach involves manual tracing of the
lesion borders that might have high inter-reader variabil-
ity, which can result in the derivation of unstable radiomic
features. In order to build more robust models, stable
Fig. 2 Feature selection is accomplished by applying several methods in a cascade manner. A typical workflow in the first phase permits only
stable features to be forwarded, then a zero or near-zero variance method is removing useless features, then a correlation analysis is removing
redundant features and finally a more sophisticated method like maximum relevance minimum redundancy (mRMR) or recursive feature
elimination (RFE) is used to craft the final Radiomic signature
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features should be identified. One way of identifying fea-
ture stability is to perform at least two radiological seg-
mentations on the same lesion, which are then analyzed
to identify the stable features using simple correlation ana-
lysis [20].
Currently, automatic disease segmentation is an active
research field [21–26], which can potentially reduce
inter-reader variability, as well as reducing the work bur-
den on radiologists to under these tasks, thereby making
the analysis large data sets more viable (Fig. 3). However,
even with automatic disease segmentation, it is import-
ant for board-certified radiologists to verify and approve
the final segmentation result.
A more recent approach is the delineation of the dif-
ferent physiologically distinct regions (e.g., blood flow,
cell density, necrosis, and edema) within the tumor, also
known as habitats [5, 27] which can be based on using
functional imaging measurements, especially MRI. The
radiomic features can then be extracted for each of these
habitats. It is also interesting that recent studies have
also found that radiomics features in peri-tumoral re-
gions can also provide novel information that informs
on treatment effects and disease outcomes.
Extracting handcrafted or deep imaging features
The primary objective of radiomics is to provide com-
prehensive assessment of the imaging phenotype using
automated data extraction algorithms. The latter can be
served by calculating a large number of quantitative im-
aging features that capture a wide variety of phenotypic
traits. Radiomic features can be classified into agnostic
and semantic [2]. Semantic features are commonly used
by radiologists to describe lesions like diameter, volume,
morphology, while agnostic features are mathematically
extracted quantitative descriptors, which are not part of
the radiologists’ lexicon. These features are identified by
algorithms that capture patterns in the imaging data,
such as first-, second-, and higher-order statistical deter-
minants, shape-based features, and fractal features. First-
order statistics can be used to describe voxel values
without concern for their spatial relationships. These
can be used to quantify phenotypic traits, such as overall
tumor intensity or density (mean and median of the vox-
els), or variations (range or entropy of the voxels). There
is also shape- and location-specific features that capture
3-dimensional shape characteristics of the tumor.
Second-order statistical features takes into account the
spatial relationships of the image contrast between vox-
els. They are also referred to as texture features [28].
Texture is defined as “a regular repetition of an element
or pattern on a surface with the characteristics of bright-
ness, color, size, and shape.” Examples of texture fea-
tures include the gray-level co-occurrence matrix, gray-
level dependence matrix, gray-level run-length matrix,
Fig. 3 A convolutional neural network (VNet architecture) was trained on arterial phase images of a dynamic contrast enhanced MRI dataset to
automatically segment enhancing breast lesions. Two examples are shown (the worst and the best) with an average DICE coefficient of 0.82 ±
0.15. The pink color denotes the pixels that where considered from the network as a lesion while the white pixels where corresponding to the
radiologists’ segmentation used as the ground truth. The DICE coefficient is defined as 2 * the Area of Overlap between the pink and white areas
divided by the total number of pixels in the segmentation mask. 130 patients in total were recruited for the training of the model
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and gray-level size zone matrix [29]. These matrices de-
scribe textural differences based on grey tone spatial de-
pendencies. Advanced methods, such as wavelet and
Laplacian of Gaussian filters, can be applied to enhance
intricate patterns in the data that are difficult to quantify
by eye. When using artificial neural networks, the so
called “deep” features can be extracted during the train-
ing phase, which are very powerful for mapping non-
linear representations when there is adequate training
data volume. However, deep features suffer from low in-
terpretability, acting as black boxes and are therefore
treated with variable sceptisism because they are difficult
to conceptualise; compared with engineered or semantic
features, which are often associated with biological
underpinnings.
Reducing the dimensionality of the generated data by
feature selection methods
The high-dimensional nature of radiomics makes it sen-
sitive to the so-called “curse of dimensionality” being re-
sponsible for model overfitting [30]. It is critical to
minimize overfitting in order to build robust radiomic
signatures that are generalizable and are robust to detect
differences between new patients not used for training
the model. Various strategies have been proposed to
minimize overfitting. The most obvious is to train the
models with more data since there is a reverse linear re-
lationship between overfitting and the amount of data
used for training. In case the latter is not feasible, di-
mensionality reduction is critical to be achieved through
feature selection/reduction methods.
Feature selection methodologies can identify redun-
dant, unstable, and irrelevant imaging features and re-
move them from further analysis. In this way, the few
highly informative, robust features constituting the “sig-
nal” of the model will be employed in constructing a ro-
bust radiomic signature [31–34].
Feature stability can be assessed for consistency in the
test-retest setting, the so-called temporal stability; or in
terms of robustness of features to variations in tumor
segmentation the so-called spatial stability [31]. Another
type of stability check that needs to be considered in
case of a split-validation scheme is to compare the distri-
bution of values of each radiomic feature in the training
and test datasets, keeping only those that show no sig-
nificant difference between the two to avoid outliers or
systematic errors between the training and test sets. It is
worth keeping in mind that this type of feature selection
is unsupervised since we do not need to reveal the
ground truth variable during the process.
Following the identification of stable features, we
need to remove redundant features using a
correlation-based feature elimination method [32].
After constructing a correlation heatmap, we can
identify blocks of features (Fig. 4) that presents with
a correlation coefficient being higher than a prede-
fined threshold (i.e., 95%) and remove them. Now
that a significant number of features have been re-
moved, we proceed with more sophisticated methods
in order to further reduce the dimensionality and
construct our radiomic signature that will comprise
a few features. For the latter task, different methods
Fig. 4 Correlation analysis heatmap showing blocks of highly correlated radiomic features (black frames on the left and positive with red color or
negative correlation with blue color on the right). When identifying such groups of highly correlated features all but the one with the highest
variance are removed from further analysis. In this case, the correlation coefficient was set to 95%
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can be used. These methods can be divided into
three categories, namely filter, wrapper, and embedded
methods. Filter methods perform feature ranking, the se-
lection is based on statistical measures and are character-
ized by their computational efficiency, generalization, and
robustness to overfitting. Filter methods can either score
features independently (univariate methods), by ignoring
the relationship between features or take into account the
dependency between features (multivariate methods). Uni-
variate filter methods are usually used as a preprocessing
step since redundancy is not analyzed. In wrapper
methods, searches to identify subsets of relevant and non-
redundant features are performed, and each subset is eval-
uated based on the performance of the model generated
with the candidate subset. These methods are susceptible
to overfitting and are computationally expensive. The em-
bedded methods perform feature selection and classifica-
tion simultaneously, taking advantage of their feature
selection methods and learning, which create more accur-
ate models. By comparison with wrapper methods, em-
bedded methods are computationally efficient [33].
Usually, we construct heatmaps showing the performance
of using the different machine learning models with vari-
ous feature selection methods (Fig. 5).
Training and validating the radiomics model
Following feature selection, a set of non-redundant,
stable, and relevant features can be used to develop a
model that will try to answer the selected clinical ques-
tion, which is also called ground truth or target variable.
Depending on whether the result of the clinical question
is a continuous or a discrete variable, different methods
should be used. When working with continuous vari-
ables, regression methods, such as Linear Regression,
Cox (Proportional Hazards), Regression Trees, or others
can be used. As for discrete variables, we can use classi-
fication methods such as Logistic Regression, Naïve
Bays, Support Vector Machines, Decision Trees, Ran-
dom Forests, K-nearest neighbors and others [34]. To
estimate the performance of the trained model, we
should ideally have two distinct patient cohorts. The lar-
ger should be used for training and fine-tuning the
model, while the smaller, ideally from a different institu-
tion, should be used to validate the model. The latter
provides external validation that will result in more real-
istic estimates of the model’s performance. This ensures
that we able to develop radiomics signatures that can be
applied across clinical settings. Unfortunately, very few
published models are developed using external validation
Fig. 5 A heatmap aggregating the performance results of combinations of 6 machine learning models and 9 feature selection techniques. The
dataset used for this analysis comprised features extracted from malignant pancreatic neoplasms on diffusion-weighted MRI acquired at high b
value images (? of b = 900 s/mm2), which is used to distinguish patients with synchronous liver metastases from those without metastases. The
best performing combination was an LDA model with mRMR feature selection method. SVM: Support Vector Machine, GLM: General Linear
Model, LDA: Linear Discriminant Analysis, LG: Logistic Regression, NB: Naïve Bayes, KNN: K Nearest Neighbor, FSCR: Fisher Score, TSCR: T-Score,
CHSQ: CHI-Square, WLCX: Wilcoxon, Gini: Gini index, MIM: Mutual Information Maximization, mRMR: minimum Redundancy Maximum Relevance,
JMI: Joint mutual information
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counting, on average, 6%, according to a recent study
that evaluated 516 published models [35]. The vast ma-
jority of the published models are based on single-
institution retrospective patient cohorts using the so-
called internal validation. Using the latter approach, the
study cohort is divided into two different subsets, the
training subset is used to develop the model, while the
testing subset is used only for the validation and evalu-
ation of the model derived from the training subset. In
the case of a very small dataset (between 50 and 100 pa-
tients), the internal validation approach has a significant
risk of bias since a single test set comprising a few dozen
data points (i.e., 20–30 patients) can easily provide over
optimistic or pessimistic estimates of model
performance.
One way to deal with this problem is to utilize a cross-
validation approach that comprises the separation of the
small cohort into multiple training and testing sets [33].
In k-fold cross-validation, the original sample is ran-
domly partitioned into k equal sized subsamples (Fig. 6).
Of the k subsamples, a single subsample is retained as
the validation data for testing the model, and the
remaining k − 1 subsamples are used as training data.
The cross-validation process is then repeated k times
(the folds), with each of the k subsamples used exactly
once as the validation data. The k results from the folds
can then be averaged to produce a single estimation.
Apart from the average performance of a model, the
standard deviation computed across the folds should be
reported since that is a measure of the model’s reprodu-
cibility and robustness. It is often the case when
comparing multiple models, to choose the one with
slightly inferior performance but significantly lower
standard deviation since this model will be potentially
more robust and reproducible.
There are two main types of learning schemes in
radiomics; the supervised learning where the model de-
velopment is based both on input (radiomic features)
and output data (ground truth variable), and the un-
supervised learning approach where the model is trying
to reveal potential associations or correlations using only
the input data. A typical example of the latter is the hier-
archical cluster analysis that has been applied to find as-
sociations between imaging features and gene
expressions in the so-called radiogenomic models, where
several sets of imaging features may be observed in asso-
ciation with specific gene expressions.
In general, radiomic features can be investigated
alongside many other -omics types of data, including
proteomics, metabolomics, and others. Integration of
multiple, diverse sources of data using different kind of
fusion strategies either at a feature or at a model deci-
sion level is a current trend in predictive modeling. In
particular, it is very common to add radiomic features to
clinical variables that are predictors of the disease out-
come in the form of nomograms [36–38], which can
then be applied and tested within clinical cohorts.
Conclusions
The impetus for developing a radiomics signature often
arise from unmet clinical needs in disease detection,
characterization, staging, as well as prediction of treatment
Fig. 6 Resampling scheme based on the total dataset and iterative multi-splitting scheme based on a 5-fold cross validation. Apart the
performance metric (mean AUC in that case) it is of equal importance to report the standard deviation across the folds to get an indication of
robustness of the model. Low standard deviations are reflecting stable and robust models that are not influenced by the specific test set
Papanikolaou et al. Cancer Imaging           (2020) 20:33 Page 8 of 10
response and disease survival. The approach to radiomics
should follow best practices not only generic to data science
but also take into consideration domain related conditions,
particularly when dealing with smaller datasets that are fre-
quently encountered in cancer imaging. Optimal radiomics
analysis in cancer imaging requires a multidisciplinary ap-
proach, involving expert knowledge of Oncologists, Radiol-
ogists, Imaging Scientists and Data Scientists. There is a
cogent need for radiologists to drive these projects through
domain knowledge which has key influence on many parts
of the workflow and the eventual outcome.
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